SEC Form 4 · accession 0001104659-17-064753
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Bisgaard
Director
Period of report
Oct 26, 2017
Accepted (ET)
Oct 30, 2017 · 9:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $22.37 | Oct 26, 2017 | A | 15,000 | A | — | Oct 26, 2027 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1On October 26, 2017, the Reporting Person was granted an option to purchase 15,000 shares of Common Stock. The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 20, 2018 or (ii) the Issuer's annual general meeting of shareholders in 2018.